| Dr Smita N Kargutkar, MD | |
|
225 Highway 35 North, Suite 102-b, Red Bank, NJ 07701 | |
| (732) 413-8000 | |
| (732) 400-6745 |
| Full Name | Dr Smita N Kargutkar |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 24 Years |
| Location | 225 Highway 35 North, Red Bank, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043482631 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA09246000 (New Jersey) | Secondary |
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 25MA09246000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Monmouth Medical Center | Long branch, NJ | Hospital |
| Bayshore Medical Center | Holmdel, NJ | Hospital |
| Riverview Medical Center | Red bank, NJ | Hospital |
| Ocean Medical Center | Brick, NJ | Hospital |
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ace Endocrinology Associates Professional Corp | 4880992155 | 2 |
News Archive
Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.
› Verified 2 days ago
| Entity Name | Barnabas Health Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.
› Verified 2 days ago
| Entity Name | Ace Endocrinology Associates Professional Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457716862 PECOS PAC ID: 4880992155 Enrollment ID: O20160420000646 |
News Archive
Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Smita N Kargutkar, MD 225 Highway 35 North, Suite 102-b, Red Bank, NJ 07701 Ph: (732) 413-8000 | Dr Smita N Kargutkar, MD 225 Highway 35 North, Suite 102-b, Red Bank, NJ 07701 Ph: (732) 413-8000 |
News Archive
Human Genome Sciences, Inc. today announced that it has received preliminary written feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) seeking approval in the United States to market 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. FDA has expressed concerns regarding the risk benefit assessment of ZALBIN dosed at 900-mcg every two weeks.
Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.
QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.
Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.
› Verified 2 days ago
Dr. Anuradha Thalasila, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 157 Broad St Ste 317, Red Bank, NJ 07701 Phone: 732-530-2960 Fax: 732-530-7446 | |
Dr. Khalid M Ahmad, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: One Riverview Plaza 2 West, Riverview Medical Center, Red Bank, NJ 07701 Phone: 732-530-2421 | |
Rosemary D Gorman, APN Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 205 Rutledge Dr, Red Bank, NJ 07701 Phone: 732-687-7632 Fax: 732-796-7123 | |
Mrs. Anca Marie Salaru, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 157 Broad St, Suite 317, Red Bank, NJ 07701 Phone: 732-530-2960 Fax: 732-530-7446 | |
Robert John Gialanella, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 365 Broad St, Red Bank, NJ 07701 Phone: 732-842-4294 Fax: 732-842-3854 | |
Dr. Vikranta Sharma, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 176 Riverside Ave, Red Bank, NJ 07701 Phone: 723-224-6868 Fax: 732-224-0843 |